Cibinqo (abrocitinib) is an oral JAK1 inhibitor for moderate-to-severe atopic dermatitis, taken once daily as 50 mg, 100 mg or 200 mg tablets, and it ships without a cold chain.
M Care Exports supplies Cibinqo (abrocitinib), marketed by Pfizer, to hospital pharmacies, dermatology units, importers and tender desks in the GCC, Africa and the UK. If you are looking for the 50 mg, 100 mg or 200 mg tablets, send the destination, the strength and the quantity, and we quote per destination.
Abrocitinib exporter and bulk supplier from India.
"I'm looking for Cibinqo 200 mg" is a typical enquiry, and the strength needs a second look before it is ordered. The US label starts at 100 mg once daily and considers 200 mg for patients who do not respond. The UK SmPC allows a 100 mg or 200 mg start, with 100 mg recommended for adolescents aged 12 to 17 and for patients at higher risk of venous thromboembolism, major cardiovascular events or malignancy, and 100 mg for patients aged 65 and over, who should receive it only if no suitable alternative exists. A dermatology unit may therefore need 100 mg and 200 mg lines together, and 50 mg for the renal and CYP2C19 dose adjustments both labels describe. The quote turns on the strength mix, the pack format, the quantity, the destination's registration route and Incoterms. Cibinqo is a tablet with no refrigeration requirement on the US or UK labels, which keeps freight simpler than for the biologics in this category. M Care Exports is a merchant-exporter and quotes per destination.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Janus kinase 1 (JAK1) inhibitor, sourced and documented for export.
Cibinqo is a Janus kinase 1 (JAK1) inhibitor taken orally. The US label (Pfizer, DailyMed, revised September 2026) lists 50 mg, 100 mg and 200 mg pink film-coated tablets. The UK emc publishes separate SmPCs for the 50 mg, 100 mg and 200 mg film-coated tablets, held by Pfizer Limited. The EMA page records authorisation for moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy, with Pfizer Europe MA EEIG as the holder and authorisation dated 9 December 2021. The US indication is narrower in wording: refractory, moderate-to-severe atopic dermatitis in adults and paediatric patients 12 years and older whose disease is not adequately controlled with other systemic drugs, including biologics, or when those are inadvisable. The US label carries a boxed warning on serious infections, mortality, malignancy, major adverse cardiovascular events (MACE) and thrombosis. It is not recommended with other JAK inhibitors, biologic immunomodulators or other immunosuppressants.
Active ingredient
Abrocitinib. Janus kinase 1 (JAK1) inhibitor.
Forms and strengths
50 mg film-coated tablet; 100 mg film-coated tablet; 200 mg film-coated tablet.
Indications
Abrocitinib is an oral JAK1 inhibitor indicated for moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older. Supplied as an originator brand (Cibinqo, Pfizer) to licensed importers, hospital pharmacies and tender desks.
Administration
Oral. Film-coated tablet.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers are hospital pharmacists in dermatology and immunology units, MoH and hospital tender desks, and licensed importers and distributors in the GCC, Africa and the UK. Typical enquiries read "I'm looking for Cibinqo 100 mg tablets for a dermatology clinic" or "We need a partner for abrocitinib for a hospital tender". Each destination has its own registration or import route, for example the Emirates Drug Establishment (EDE) in the UAE, NAFDAC in Nigeria and the MHRA in the UK. Whether Cibinqo is registered in a given country, or has to come in as an unlicensed or named-patient import, depends on that regulator, and M Care Exports confirms the route per enquiry before quoting.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on abrocitinib.
Read the label for the market you are supplying, because the texts differ. The US label starts at 100 mg once daily, considers 200 mg for non-responders, and asks for the lowest efficacious dose to maintain response. It sets pre-treatment blood thresholds (platelets below 150,000/mm3, lymphocytes below 500/mm3, neutrophils below 1,000/mm3 or haemoglobin below 8 g/dL means initiation is not recommended) and asks for a blood count at baseline, at 4 weeks and 4 weeks after any dose increase. It does not recommend the drug in severe renal impairment, and it contraindicates antiplatelet therapy other than low-dose aspirin (81 mg daily or less) for the first 3 months. The UK SmPC instead lets severe renal impairment start at 50 mg once daily with a 100 mg ceiling, and contraindicates active serious systemic infection including tuberculosis, severe hepatic impairment, pregnancy and breast-feeding. Strong CYP2C19 inhibitors such as fluvoxamine or fluconazole cut the dose: to 50 mg once daily on the US label, and by half, to 100 mg or 50 mg, on the UK SmPC. Storage is 20 to 25 °C on the US label, and the UK SmPC states no special storage restrictions and a 4-year shelf life.
The documentation pack a regulator actually asks for.
Cibinqo needs no cold chain on the labels we cite: the US label gives 20 to 25 °C in the original package, with excursions permitted between 15 and 30 °C, and the UK SmPCs state no special storage restrictions. The UK SmPCs for the 50 mg, 100 mg and 200 mg tablets give a 4-year shelf life and list HDPE bottles of 14 or 30 tablets and PVDC blisters in packs of 14, 28 or 91, noting that not all sizes may be marketed. The US label lists 30-count bottles for each strength. The EMA page shows the safety restrictions that apply in the EU, including use in patients aged 65 or older only if no suitable alternative exists, and restricted use in patients with cardiovascular risk factors or at increased cancer risk. M Care documentation covers batch certificates of analysis, export documents and destination-aligned dossier support where the regulator asks for it. We state the source and status of each line before quoting, and we make no WHO-GMP or WHO prequalification claim for ourselves.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside abrocitinib.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for abrocitinib.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Abrocitinib supply, the specific questions.
What is Cibinqo 200 mg, and when is it used?
Cibinqo 200 mg is the highest of the three tablet strengths, taken once daily. The US label starts patients at 100 mg and recommends 200 mg once daily for patients not responding to 100 mg. The UK SmPC allows a 100 mg or 200 mg start, with 200 mg suited to patients who are not at higher risk and have a high disease burden or an inadequate response to 100 mg, and says the dose should be reduced to 100 mg once disease is controlled. M Care Exports supplies all three strengths and quotes per destination.
What is the Cibinqo dosing for atopic dermatitis?
The US label recommends 100 mg orally once daily, with or without food and swallowed whole, and considers 200 mg once daily for non-responders. It advises the lowest efficacious dose. For moderate renal impairment and CYP2C19 poor metabolisers it gives 50 mg once daily, rising to 100 mg if response is inadequate. The UK SmPC gives a 100 mg or 200 mg starting dose, recommends 100 mg for ages 12 to 17, and halves the dose with strong CYP2C19 inhibitors. Dosing is the prescriber's decision under the destination's label.
Cibinqo price: what sets the cost for an importer?
We do not publish a price. The landed cost of Cibinqo for an importer depends on the strength mix, pack format, quantity, the destination's registration route and the Incoterms. Cibinqo needs no refrigeration on the US and UK labels, so cold-chain packing is not a cost driver as it is for biologics. M Care Exports quotes per destination once we have the strength, quantity and country, and states the source and status of the line in the offer.
Cibinqo vs Rinvoq: how do the labels compare?
On label facts only: Cibinqo (abrocitinib) is a JAK1 inhibitor given as 50 mg, 100 mg or 200 mg tablets once daily, and Pfizer's label covers atopic dermatitis. Rinvoq (upadacitinib, AbbVie) is a JAK inhibitor given as once-daily extended-release tablets, and its US atopic dermatitis dosing is 15 mg or 30 mg, within a label that lists further indications. Both US labels cover atopic dermatitis from 12 years of age, and both carry JAK-class warnings. This is not a recommendation for either product. See our upadacitinib page.
Is Cibinqo used for eczema?
Atopic dermatitis, which the EMA notes is also known as eczema, is the labelled use. The EMA and UK texts cover moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy, and the US label covers refractory, moderate-to-severe atopic dermatitis in the same age range. Other types of eczema are not labelled indications for Cibinqo, and we do not suggest using it that way. It is a prescription medicine, supplied to licensed importers and hospitals.
Does Cibinqo have a boxed warning, and is a generic available?
The US label carries a boxed warning on serious infections, mortality, malignancy, major adverse cardiovascular events and thrombosis. The higher rates of mortality, malignancy, MACE and thrombosis come from a trial of another JAK inhibitor in rheumatoid arthritis, a disease Cibinqo is not approved for, and the label notes that malignancy, MACE and thrombosis have also occurred with Cibinqo. In the EU, the EMA page restricts use in patients aged 65 or older, with cardiovascular risk factors or at increased cancer risk. The labels we cite are all for the Pfizer originator. If you are looking for a generic, tell us the destination and M Care Exports confirms what can lawfully be supplied there.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-11-08.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.